BPC-157: Discovery and Regulatory History How BPC-157 traveled from a 1993 gastric-cytoprotection hypothesis at the University of Zagreb, through Pliva's PL14736 clinical program, to research-use-only status and a 2022 WADA Monitoring Program listing
On sale, save 0% 125.00 125.00 Was 125.00 Also available as a re-constitutable powder FREE delivery by Friday, July 31 2026 (orders over 100) Fastest delivery by Wednesday, July 29 2026
Extant studies have found that AS-IV has protective effects on the kidneys and improves renal fibrosis by enhancing the expression of phosphorylated (p-) Smad3 C/p21 and nuclear factor (erythroid-derived 2)-like 2(Nrf2)/Heme oxygenase-1(HO-1), thereby inhibiting p-Smad 3L/plasminogen activator inhibitor (PAI)-1 and reducing ROS and -SMA levels (Qin et al., 2023)
10.1101/gad.275891.115 104 JiaJ.ShiY.ChenL.LaiW.YanB.JiangY.et al (2017)
3 Watanabe F, Hashizume E, Chan GP, Kamimura A
(3) Minor risk factors: APOE promoter , NPSR1
